![](/wp-content/uploads/rapidlogo.png)
November 19, 2019
BURLINGTON, Ontario – November 19, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported that is has been issued a micro-processing licence by Health Canada for its Burlington, Ontario facility in accordance with the Cannabis Act and Cannabis Regulations. “This...
![](/wp-content/uploads/rapidlogo.png)
October 30, 2019
BURLINGTON, Ontario – October 30, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported its financial results for the second quarter of fiscal 2020, which ended on August 31, 2019. “We are very pleased to announce the recognition of revenue...
![](/wp-content/uploads/rapidlogo.png)
October 9, 2019
BURLINGTON, Ontario, October 9, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) is pleased to announce that today it has completed the first closing of a private placement of common shares in the capital of the Corporation (“Common Shares”) at a...
![](https://rapid-dose.com/wp-content/uploads/unlv-logo.jpg)
September 12, 2019
Burlington, ON, September 12, 2019 — Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the results of a research study conducted by the University of Nevada, Las Vegas (“UNLV”) was published in the high impact journal, Frontiers in Pharmacology, on September 10, 2019....
![](/wp-content/uploads/rapidlogo.png)
September 10, 2019
Burlington, Ontario – September 10, 2019 – Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the installation and commissioning of its QuickStrip™ production equipment at Aphria Inc. (“Aphria”) (TSX: APHA and NYSE: APHA) has been completed pursuant to the terms of the Managed...
![](/wp-content/uploads/rapidlogo.png)
September 4, 2019
Burlington, Ontario – September 4, 2019 – Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the installation of its QuickStrip™production equipment at Chemesis International Inc. (“Chemesis”) (CSE: CSI) (OTC: CADMF) (FRA: CWAA) is now complete, enabling the immediate recognition of revenue to RDT...
![](/wp-content/uploads/rapidlogo.png)
August 20, 2019
Burlington, ON, August 20, 2019 — Rapid Dose Therapeutics Corp. (CSE: DOSE), (“RDT”) announced today the commencement of a clinical research trial with the GI Research Institute (“GIRI”) and the University of British Columbia (“UBC”) under the direction of Dr. Brian L. Bressler, MD, as...
![](/wp-content/uploads/rapidlogo.png)
August 8, 2019
Burlington, ON, Brantford, ON, August 8, 2019 — Rapid Dose Therapeutics Corp. (CSE: DOSE), (“RDT”) announced today that they have signed a Manufacturing Agreement (“the Agreement”) with Thrive Cannabis (“Thrive”) to produce QuickStrip™ cannabis products for both the Canadian medical and recreational markets. This Agreement...
![](/wp-content/uploads/rapidlogo.png)
August 1, 2019
Burlington, ON, August 1, 2019 — Rapid Dose Therapeutics Corp. (CSE: DOSE), (“RDT”) announced today that they have signed an amendment to the 12 month distribution agreement (the “Agreement”) with Ukraine Pharma to expand the marketing and distribution of QuickStrip™ nutraceutical products to seven additional...
![](/wp-content/uploads/rapidlogo.png)
July 30, 2019
BURLINGTON, Ontario – July 30, 2019 – Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) today reported its financial results for the first quarter of fiscal 2020, which ended on May 31, 2019. “This quarter represents a very exciting milestone for RDT as we commence the...